Next Article in Journal
Effect of Chicken Egg White-Derived Peptide and Hydrolysates on Abnormal Skin Pigmentation during Wound Recovery
Next Article in Special Issue
Chemical Synthesis and Biological Evaluation of 3-Substituted Estrone/Estradiol Derivatives as 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors Acting via a Reverse Orientation of the Natural Substrate Estrone
Previous Article in Journal
Design of Novel Coumarin Derivatives as NUDT5 Antagonists That Act by Restricting ATP Synthesis in Breast Cancer Cells
Previous Article in Special Issue
Straightforward Access to a New Class of Dual DYRK1A/CLK1 Inhibitors Possessing a Simple Dihydroquinoline Core
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 28
Issue 1
10.3390/molecules28010091
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Investigation on Hydrazonobenzenesulfonamides as Human Carbonic Anhydrase I, II, IX and XII Inhibitors

by
Davide Moi
1,
Serena Vittorio
2,
Andrea Angeli
3,
Gianfranco Balboni
1,
Claudiu T. Supuran
3 and
Valentina Onnis
1,*
1
Department of Life and Environmental Sciences, University of Cagliari, University Campus, S.P. 8 CA, 09042 Monserrato, Italy
2
Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano,Via Mangiagalli 25, 20133 Milano, Italy
3
Laboratorio di Chimica Bioinorganica, Polo Scientifico Neurofarba Department, Università Degli Studi di Firenze, Room 188, Via della Lastruccia 3, Sesto Fiorentino, 50019 Florence, Italy
*
Author to whom correspondence should be addressed.
Molecules 2023, 28(1), 91; https://0-doi-org.brum.beds.ac.uk/10.3390/molecules28010091
Submission received: 5 December 2022 / Revised: 19 December 2022 / Accepted: 21 December 2022 / Published: 22 December 2022
(This article belongs to the Special Issue Enzyme Inhibitors: Design, Synthesis and Biological Evaluation)
Browse Figures
Versions Notes

Abstract

:
A small series of hydrazonobenzenesulfonamides was designed, synthesized and studied for their human carbonic anhydrase (hCA) inhibitory activity. The synthesized compounds were evaluated against hCA I, II, IX and XII isoforms using acetazolamide (AAZ) as the standard inhibitor. Various hydrazonosulfonamide derivatives showed inhibitory activity at low nanomolar levels with selectivity against the cytosolic hCA II isoform, as well as the transmembrane, tumor-associated enzymes hCA IX and XII. The most potent and selective hydrazones 8, 9, 10, 11, 19 and 24 were docked into isoforms I, II, IX and XII to better understand their activity and selectivity for the different CA isoforms.

1. Introduction

Human carbonic anhydrases (hCAs) belong to the alpha CA class and are zinc-containing enzymes which catalyze the reversible hydration of carbon dioxide to bicarbonate and a proton (CO2 + H2O ⇆ HCO3− + H+). To date, 15 diverse isoforms have been identified, which differ in molecular structure, catalytic properties, organ and tissue distribution as well as subcellular localization, and ability to interact with different inhibitor classes [1]. Different physiological and pathological functions are regulated by hCAs, such as electrolyte secretion and pH regulation, gluconeogenesis, osteoclast functionality and tumorigenicity [1,2]. Thus, hCA inhibitors can be used for the treatment of glaucoma, obesity, neuropathic pain, arthritis, Alzheimer’s disease and cancer. The cytosolic isoforms hCA I and hCA II are widely expressed in erythrocytes, eyes, gastrointestinal tract, osteoclasts and kidney cells [2]. Some hCA II inhibitors are currently used as anti-glaucoma drugs and as mild diuretics [3]. However, the hCA I and II isoforms are considered off-targets in the development of inhibitors for the transmembrane, tumor-associated hCA IX and XII isoforms [4]. Despite the prominent role of hCA II in the regulation of intraocular pressure, anti-glaucoma agents also decrease bicarbonate and aqueous humor secretion by inhibition of hCA I, IV and XII [5,6,7]. hCA II activity has been also associated with neurodegeneration and aging processes [8] and altered hCA II expression constitutes a biomarker of carcinogenesis in some human tumors [9]. The transmembrane hCA IX and XII, among others, are involved in tumorigenesis (hCA IX and XII) and glaucoma (hCA II and XII). Under physiological conditions, the expression of hCA isoform IX is restricted to the basolateral membrane of epithelial cells of the gastric, intestinal and gallbladder mucosa [10] as well as in specialized cells of the ovaries and testes, in some sites of the peripheral and central nervous systems and in mesodermal cells of the placenta and cartilaginous tissues of joints [11,12]. A very low expression of hCA XII is present in tissues such as kidney, pancreas, colon, prostate, ovary, testis, endometrium, lung, brain and colon [13,14,15,16] and is associated with rapid tumor growth, metastasis and infiltration into surrounding normal tissues [17,18,19].
Hydrazones have been extensively studied due to their wide biological activities [20,21,22,23,24,25,26,27] while a urea group is a commonly incorporated tailing linker in benzenesulfonamide CA inhibitors. The hydrazone group is a urea-bioisostere, thus different groups have reported successful approaches to inhibit CA by hydrazone-based compounds [28,29,30,31,32,33,34,35,36].
As a continuation of our efforts in the design and synthesis of new potent and selective hCA Is [37,38,39,40,41], this study presents a small library of hydrazonobenzenesulfonamide-based compounds. The target compounds are endowed with a benzenesulfonamide-type zinc-binding group (ZBG) connected by a carbonyl bridge to a piperidine ring, which provides an appropriate orientation and connects the two tails with both the hydrophilic and hydrophobic halves of the active site. The hydrazone moiety can also improve the flexibility and hydrophilicity of the designed compounds to improve hCA inhibitory activity through favorable interactions with the specific residues in the hydrophilic part of the active site.

2. Results

2.1. Chemistry

The synthesis of hydrazonobenzenesulfonamide derivatives 5–29 reported here was performed as highlighted in Scheme 1, starting from 4-sulfamoylbenzoic acid 1. By using our previously reported synthetic procedure [42], the coupling of sulfanilamide 1 with ethyl piperidine-4-carboxylate 2 in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) in a dry acetonitrile solution (MeCN) produced ethyl 1-(4-sulfamoylbenzoyl)piperidine-4-carboxylate 3. This ester was treated with hydrazine hydrate in absolute ethanol (EtOH) to obtain the corresponding 4-(4-(hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide 4. Treatment of the hydrazide 4 with an equimolecular amount of appropriately substituted aldehydes in EtOH solution furnished the hydrazones 5–29 with yields of 52–98%. The spectral data are consistent with the assigned structure.
According to the literature, the presence of a downfield resonating (10.89–11.73 ppm) CH=N signal can exclusively account for the formation of E isomers [43]. The signal is split due to hindered amide rotation around the C–N bond of the acyl fragment that generates two conformers [43].

2.2. Carbonic Anhydrase Inhibition

Sulfonamidohydrazones 5–29 were tested for their ability to inhibit four human (h) CA isoforms involved in crucial physiologic/pathologic processes: the cytosolic hCA I and II and the transmembrane, tumor-associated hCA IX and XII. Table 1 shows the inhibition data of the derivatives reported here and the sulfonamide acetazolamide (AAZ) as the standard inhibitor tested using a stopped-flow CO2 hydrase assay [44].
The following structure activity relationship (SAR) may be noted regarding the inhibition data in Table 1.
The slow cytosolic isoform hCA I was effectively inhibited by a few of the new hydrazonosulfonamides reported here. The strongest inhibitory effects were observed for compounds 5, 7, 12, 13, 27, and 29 which had inhibition constants ranging between 18.5 and 45.5 nM (better than acetazolamide, AAZ, which has a KI of 250 nM against this isoform). These hydrazones possess the following benzylidene moieties: phenyl, 2-methoxyphenyl, 2,5-dimethoxyphenyl, 2,4,5-trimetoxyphenyl, 2,6-dichlorobenzyl and 4-(dimethylamino)phenyl. Another group of derivatives, including 8, 9, 11, 14, 16, 19, 20, and 22–26, showed medium-potency inhibitory activity against hCA I, with KIs in the range of 334–800 nM (Table 1). They possess 3-methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 3,4,5-trimethoxyphenyl, 2-methoxynaphthyl, 3-fluorophenyl, 4-fluorophenyl, 4-nitrophenyl, chorophenyl and dichlorophenyl benzylidene moieties.
The dominant cytosolic isoform hCA II was also effectively inhibited by many of the hydrazones reported here. The highly effective inhibitors were 5-7, 9, 12, 13, 22, 23 and 25-29, with KIs in the range of 1.75–6.65 nM. They possess phenyl, 4-methylphenyl, 4-methoxyphenyl, 2,5-dimethoxyphenyl, 2,4,5-trimethoxyphenyl, 4-nitrophenyl, 2-chlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl and 4-(dialkylamino)phenyl benzylidene moieties. As for hCA I, small structural changes between hydrazones led to dramatic differences in their inhibitory activity. For example, an impressive difference of inhibitory power was observed for the two isomeric nitrophenyl-substituted compounds 21 and 22, with the 4-nitrophenyl derivative being a 9-fold better inhibitor than its isomer with the 3-nitrophenyl group. Medium potency inhibitors included the following hydrazones: 8, 11, 14, 15, 17–19, 21, and 24 (KIs in the range of 25.2–92.4 nM) whereas the weakest hCA II inhibitor in the series was 10 (KI 159.6 nM).
hCA IX was generally effectively inhibited by the new hydrazones reported here. The best inhibitory effects were observed using compounds 10, 11, 17, 19 and 23, which had inhibition constants ranging between 15.4 and 23.4 nM (better than the reference inhibitor AAZ, which has a KI of 25 nM against this isoform). These hydrazones contain the following benzylidene moieties: 2,4-dimethoxyphenyl, 3,4-dimethoxyphenyl, 2-methoxynaphthyl, 3-fluorophenyl, 2-chlorophenyl 2,4,5-trimetoxyphenyl, 2,6-dichlorobenzyl and 4-(dimethylamino)phenyl benzylidene moieties. Another group of derivatives, including 5–8, 12-15, 18, 20, 22, 24–27 and 29 showed high-potency inhibitory activity against hCA IX, with KIs in the range of 34.3–67.5 nM. Only hydrazones 9, 16, 21 and 28 showed micromolar inhibitory potencies (KIs in the range of 123–320 nM, see the Supplementary Materials). As for hCA I and hCA II, small structural changes between hydrazones led to marked differences in their inhibitory activity. For example, a large difference in inhibitory potency was observed for the two isomeric methoxyphenyl-substituted compounds 8 and 9, with the 3-methoxyphenyl derivative being an 8-fold better inhibitor than its isomer with the 4-methoxyphenyl group.
A rather similar situation as was noted above for hCA IX has also been observed for the inhibition of the second transmembrane isoform investigated here, hCA XII. Almost all hydrazone derivatives showed efficient inhibition of this isoform (KIs in the range of 8.05–68.7 nM). The most active hydrazones incorporate the following benzylidene moieties: 2-methoxyphenyl, 2,4-dimethoxyphenyl, 3,4-dimethoxyphenyl, naphthyl and 3-fluorophenyl. The shift of the 2-methoxy group in compound 7 to the 4-position to produce hydrazone 9 results in a approx. 12-fold decrease in activity.
The unsubstituted hydrazone 5 showed no significant difference in activity towards the four tested hCA isoforms. The introduction of a 4-methyl group gave the highly hCA II-selective hydrazone 6. The replacement of the methyl by a 4-methoxy group produced a reduction in hCA II selectivity (compound 9). The shift of the methoxy group to the 2-position caused a reduction of hCA II selectivity and enhancement of hCA XII selectivity. The comparison of compound 8 and 9 activities indicated that the shift of the methoxy group to the 3-position resulted in an approx. 10- and 5-fold increase in activity against hCA IX and hCA XII, respectively, as well as an approx. 10-fold reduction in hCA II activity. The 2,4-dimethoxybenzilidene (compound 10) and the 3,4-dimethoxybenzilidene (compound 11) moieties produced high activity and selectivity against the tumor-associated hCA IX and hCA XII isoforms with hydrazone 10 as the most selective of the series towards hCA XII. The introduction of a 2-bromine atom to compound 11 (hydrazone 15) produced a slight decrease in activity on all the tested hCA isoforms. The introduction of a second methoxy group to the 5-position on compound 7 to give hydrazone 12 led to a reduction in hCA XII activity and to an improvement in hCA II activity as compared to 7. Similar inhibition data were shown by hydrazone 13 bearing a third methoxy group at the 4-position. The shift of the methoxy group to the 3-position (hydrazone 14) increased the selectivity towards hCA IX and hCA XII. The naphthyl derivative 16 showed about a 420-fold hCA XII/hCA I and 22-fold hCA XII/CA II increase in selectivity. The introduction of a methoxy group to produce hydrazone 17 increased hCA IX in activity and reduced hCA XII selectivity as compared with 16. The chlorine-substituted hydrazones displayed high hCA II selectivity except for the 3-chlorobenzylidene derivative 24 that showed about a 3-fold hCA XII/hCA II and 20-fold hCA XII/hCA I increase in selectivity.
The replacement of the methyl group on compound 6 by a 4-trifluoromethyl group reduced hCA I and hCA II selectivity (compound 18). The replacement of the 4-trifluoromethyl with a 4-fluorine atom (hydrazone 20) caused a further reduction in hCA I activity and increase of inhibitory activity against the other three hCA isoforms. The shift of the fluorine into the 3-position (hydrazone 19) produced a large increase in both activity and selectivity towards hCA IX and hCA XII. The 3-nitro-substituted hydrazone 21 showed a reduction in activity against hCA I, hCA IX and hCA XII as compared to the 3-fluorine-substituted hydrozone, while the high hCA II selectivity was maintained.

2.3. Molecular Docking

Due to their potent activity profile, the binding mode of compounds 8, 9, 10, 11, 19 and 24 to hCA isoforms II, IX and XII was investigated by docking simulations in order to rationalize the hCA isoform selectivity observed for these derivatives. All the compounds occupied the active sites of the studied hCA isoforms with the NH- and C=O groups of the sulfonamide moiety involved in the coordination of the Zn ion and in H-bonds with Thr199 or 200, respectively. As discussed above, derivative 9 showed the best selectivity profile towards hCA II which decreased when the 4-methoxy group was shifted to the 3-position as in compound 8, for which an increase in affinity towards hCA IX and hCA XII was observed. Both compounds might occupy the hCA II-binding pocket by engaging hydrophobic interactions with Phe131 and a H-bond with Asn67 (Figure 1A).
The main differences between the two binding poses rely on the different orientations assumed by the benzensulfonamide moiety and the tail of the molecules. More specifically, in compound 8 the former could be involved in hydrophobic contacts with Val121 while no interactions were observed for the tail portion. In the case of inhibitor 9, the arylsulfonamide moiety might be stabilized by π-stacking interactions with His94, while the tail is oriented towards Leu57 which establishes hydrophobic contacts with the methoxy group and might contribute to further stabilization of the binding to the hCA II active site. When bound to hCA IX (Figure 1B), hydrazone 9 might form hydrophobic contacts with Pro199 through the phenyl ring of the tail, while additional interactions were observed for the 3-methoxy-substituted analogue 8 which might elicit several hydrophobic contacts with Leu198, Val121, Pro202, Gln2 and Val19 and a H-bond with Trp5, thus explaining its higher affinity towards hCA IX compared to compound 9. Despite these two inhibitors showing similar binding modes to the hCA XII active site (Figure 1C), the 3-methoxy group of hydrazone 8 allowed the formation of a convenient H-bond with His64 that was not observed for hydrazone 9 and this might be the reason for the higher inhibitory activity of derivative 8 towards hCA XII.
Hydrazones 10, 11, 19 and 24 displayed a good selectivity towards the tumor-associated isoforms hCA IX and hCA XII over hCA II. As shown in Figure 2, these hydrazones might bind the hCA II active site by establishing hydrophobic interactions with Phe131 through the piperidine ring, which might also be stabilized by additional contacts with Pro202 and Ile91 in the case of compounds 11 and 24, respectively.
Other hydrophobic interactions were observed between the benzensulfonamide moiety of hydrazone 11 and Leu198 and Val121. Furthermore, hydrazones 10, 19 and 24 might engage a H-bond between the side chain of Asn67 and the amide carbonyl group. No relevant interactions were observed between the tails of derivatives 10, 11, 19 and 24 and the rim of the hCA II active site. Conversely, a major stabilization of these molecules’ tails was observed in the docking simulations performed with the hCA IX and hCA XII binding pockets, which can explain the major affinity of these compounds towards the tumor-associated isoforms. Specifically, the four inhibitors might assume similar binding orientations within the hCA IX active site (Figure 3), with the benzensulfonamide moiety and the piperidine ring engaging hydrophobic contacts with Val121, Leu198 and Val131, while the tails occupy a region lined by Gln2, Ser3, Trp5, Val19, Ser20, Pro198 and Pro199, which are involved in hydrophobic interactions with these inhibitors. Moreover, hydrazones 10 and 11 could form a H-bond with Gln92 through the amide carbonyl group (Figure 3A,B), while the fluorine atom of compound 19 might elicit halogen bonds with Val19 and Gln2 (Figure 3C). These additional interactions exerted by hydrazones 10, 11 and 19 might explain their high potency towards hCA IX compared to derivative 24.
Regarding hCA XII (Figure 4), compounds 10, 11, 19 and 24 could establish hydrophobic contacts with Leu198 and Val121 through their phenyl moiety and with Ala131 through the piperidine ring. Moreover, derivatives 11 and 24 might elicit H-bonds with Thr91 and Ser132 through one of their carbonyl group and hydrazone nitrogen (Figure 4B,D), while compound 10 might engage H-bonds with Trp5 and Tyr20 through its two methoxy groups (Figure 4A). Conversely, hydrazone 19 interacts with Gln92 and Ser135 by forming hydrogen bonds with its two carbonyl groups (Figure 4C). Finally, hydrophobic interactions were detected between: (i) His64 and the 2-methoxy group of compound 10; (ii) Tyr123 and the 3-methoxy group of hydrazone 11; and (iii) Pro202 and the 3-fluorophenyl ring of compound 19.

3. Materials and Methods

3.1. Chemistry

All commercially available solvents and reagents were used without further purification. 1H NMR spectra were recorded using an Inova 500 spectrometer (Varian, Palo Alto, CA, USA). 13C NMR spectra were recorded using a Bruker Advance III HD 600 (Bruker, Bremen, Germany) at 126 MHz. The chemical shifts (δ) are reported in parts per million downfield from tetramethylsilane (TMS), which was used as an internal standard. The spectra were recorded in hexadeuteriodimethylsulphoxide (DMSO-d6). Infrared spectra were recorded using a Vector 22 spectrometer (Bruker, Bremen, Germany) in Nujol mulls. The main bands are given in cm−1. Positive-ion electrospray ionization (ESI) mass spectra were recorded using a double-focusing MAT 95 instrument (Finnigan, Waltham, MA, USA) with BE geometry. Melting points (mp) were determined with a SMP1 Melting Point apparatus (Stuart Scientific, Stone, UK) and are uncorrected. All products reported showed 1H NMR spectra in agreement with the assigned structures. The purity of the tested compounds was determined by combustion elemental analyses conducted by the Microanalytical Laboratory of the Chemistry Department of the University of Ferrara with a MT-5 CHN recorder elemental analyzer (Yanagimoto, Kyoto, Japan) and the values found were within 0.4% of theoretical values. 4-(4-(Hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (4) was synthesized as previously reported [42].

3.1.1. General Procedure for the Preparation of (E)-4-(4-(2-benzylidenehydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamides (5-25)

A mixture of 4-(4-(hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (4) (0.33 g, 1 mmol) and the appropriate arylaldehyde (1 mmol) in absolute ethanol (EtOH) (5 mL) was refluxed overnight. After cooling, the formed precipitate was filtered off and recrystallized from EtOH to give the hydrazones 5–29.

(E)-4-(4-(2-benzylidenehydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (5)

Yield 97%, M.p.> 250°C. 1H NMR (DMSO-d6) 1.59 (br s, 2H, CH), 1.73 (br s, 1H, CH), 1.88 (br s, 1H, CH), 2.99 (br s, 1H, CH), 3.20 (br s, 1H, CH), 3.44 (br s, 1H, CH), 3.50 (br s, 1H, CH), 4.48 (br s, 1H, CH), 7.39 (m, 3H, Ar), 7.42 (s, 2H, NH2), 7.57 (d, J = 8.0 Hz, 2H, Ar), 7.65 (m, 2H, Ar), 7.87 (d, J = 8.0 Hz, 2H, Ar), 7.97, 8.18 (s, 1H, NH), 11.23, 11.37 (s, 1H, CH). IR (Nujol) 3209, 3066, 1676, 1561 cm−1. Elemental analysis: calculated for C20H22N4O4S (414.48) %C 57.96, %H 5.35, %N 13.52, found %C 58.01, %H 5.33, %N 13.48. m/z 415.

(E)-4-(4-(2-(4-methylbenzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (6)

Yield 89%, M.p. >250°C. 1H NMR (DMSO-d6) 1.58 (br s, 2H, CH), 1.71 (br s, 1H, CH), 1.87 (br s, 1H, CH), 2.31 (s, 3H, CH3), 2.91 (br s, 1H, CH), 3.17 (br s, 1H, CH), 3.42 (br s, 1H, CH), 3.52 (br s, 1H, CH), 4.48 (br s, 1H, CH), 7.23 (d, J = 8.5 Hz, 2H, Ar), 7.42 (s, 2H, NH2), 7.53 (d, J = 8.0 Hz, 2H, Ar), 7.57 (d, J = 8.5 Hz, 2H, Ar), 7.87 (d, J = 8.0 Hz, 2H, Ar), 7.95, 8.14 (s, 1H, NH), 11.15, 11.30 (s, 1H, CH). IR (Nujol) 3328, 3227, 1675, 1557 cm−1. Elemental analysis: calculated for C21H24N4O4S (428.50) %C 58.86, %H 5.65, %N 13.07, found %C 58.80, %H 5.67, %N 13.11. m/z 429.

(E)-4-(4-(2-(2-methoxybenzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (7)

Yield 77%, M.p. 234-235°C. 1H NMR (DMSO-d6) 1.58 (br s, 2H, CH), 1.71 (br s, 1H, CH), 1.86 (br s, 1H, CH), 2.87 (br s, 1H, CH), 3.20 (br s, 1H, CH), 3.42 (br s, 1H, CH), 3.51 (br s, 1H, CH), 3.82 (s, 3H, OCH3), 4.47 (br s, 1H, CH), 6.97 (t, J = 7.0 Hz, 1H, Ar), 7.07 (d, J = 8.0 Hz, 1H, Ar), 7.37 (d, J = 7.0 Hz, 1H, Ar), 7.42 (s, 2H, NH2), 7.57 (d, J = 8.0 Hz, 2H, Ar), 7.77 (t, J = 7.5 Hz, 1H, Ar), 7.86 (d, J = 7.5 Hz, 2H, Ar), 8.32, 8.52 (s, 1H, NH), 11.19, 11.36 (s, 1H, CH). IR (Nujol) 3333, 3287, 3234, 1643, 1528 cm−1. Elemental analysis: calculated for C21H24N4O5S (444.50) %C 56.74, %H 5.44, %N 12.60, found %C 56.79, %H 5.43, %N 12.57. m/z 445.

(E)-4-(4-(2-(3-methoxybenzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (8)

Yield 95%, M.p. 243-244°C. 1H NMR (DMSO-d6) 1.59 (br s, 2H, CH), 1.72 (br s, 1H, CH), 1.87 (br s, 1H, CH), 2.88 (br s, 1H, CH), 3.25 (br s, 1H, CH), 3.43 (br s, 1H, CH), 3.53 (br s, 1H, CH), 3.77 (s, 3H, OCH3), 4.47 (br s, 1H, CH), 6.97 (s, 1H, Ar), 7.20 (d, J = 7.5 Hz, 2H, Ar), 7.32 (m, 1H, Ar), 7.42 (s, 2H, NH2), 7.57 (d, J = 8.0 Hz, 2H, Ar), 7.87 (d, J = 7.0 Hz, 2H, Ar), 7.94, 8.15 (s, 1H, NH), 11.25, 11.38 (s, 1H, CH). 13C NMR (DMSO-d6) 28.3, 28.9, 40.4, 46.9, 55.4, 104.6, 107.7, 111.1, 126.3, 127.7, 129.9, 139.9, 141.3, 145.1, 155.7, 160.1, 168.3, 174.2. IR (Nujol) 3210, 3067, 1678, 1560 cm−1. Elemental analysis: calculated for C21H24N4O5S (444.50) %C 56.74, %H 5.44, %N 12.60, found %C 56.69, %H 5.45, %N 12.65. m/z 445.

(E)-4-(4-(2-(4-methoxybenzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (9)

Yield 81%, M.p. 228-230°C. 1H NMR (DMSO-d6) 1.58 (br s, 2H, CH), 1.71 (br s, 1H, CH), 1.87 (br s, 1H, CH), 2.87 (br s, 1H, CH), 3.21 (br s, 1H, CH), 3.42 (br s, 1H, CH), 3.52 (br s, 1H, CH), 3.78 (s, 3H, OCH3), 4.48 (br s, 1H, CH), 6.97 (d, J = 7.0 Hz, 2H, Ar), 7.43 (s, 2H, NH2), 7.59 (m, 4H, Ar), 7.88 (d, J = 8.0 Hz, 2H, Ar), 7.93, 8.12 (s, 1H, NH), 11.11, 11.25 (s, 1H, CH). 13C NMR (DMSO-d6) 28.4, 37.9, 41.1, 55.8, 141.8, 126.4, 127.33, 127.3, 127.8, 128.8, 129.0. 140.0, 143.3, 145.1, 146.7, 161.0, 161.2, 168.3, 170.42, 175.6. IR (Nujol) 3310, 3248, 1667, 1556 cm−1. Elemental analysis: calculated for C21H24N4O5S (444.50) %C 56.74, %H 5.44, %N 12.60, found %C 56.79, %H 5.46, %N 12.56. m/z 445.

(E)-4-(4-(2-(2,4-dimethoxybenzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (10)

Yield 98%, M.p. 208-210°C. 1H NMR (DMSO-d6) 1.57 (br s, 2H, CH), 1.70 (br s, 1H, CH), 1.85 (br s, 1H, CH), 2.92 (br s, 1H, CH), 3.08 (br s, 1H, CH), 3.39 (br s, 1H, CH), 3.51 (br s, 1H, CH), 3.81 (s, 6H, OCH3), 4.46 (br s, 1H, CH), 6.58 (d, J = 8.5 Hz, 2H, Ar), 7.42 (s, 2H, NH2), 7.56 (d, J = 8.0 Hz, 2H, Ar), 7.70 (s, 1H, Ar), 7.87 (d, J = 8.0 Hz, 2H, Ar), 8.22, 8.42 (s, 1H, NH), 11.04, 11.22 (s, 1H, CH). IR (Nujol) 3348, 3251, 1659, 1558 cm−1. Elemental analysis: calculated for C22H26N4O6S (474.16) %C 55.68, %H 5.52, %N 11.81, found %C 55.74, %H 5.51, %N 11.78. m/z 475.

(E)-4-(4-(2-(3,4-dimethoxybenzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (11)

Yield 76%, M.p. >250°C. 1H NMR (DMSO-d6) 1.55 (br s, 2H, CH), 1.72 (br s, 1H, CH), 1.83 (br s, 1H, CH), 2.92 (br s, 1H, CH), 3.11 (br s, 1H, CH), 3.36 (br s, 1H, CH), 3.54 (br s, 1H, CH), 3.82 (s, 6H, OCH3), 4.45 (br s, 1H, CH), 6.56 (d, J = 8.5 Hz, 2H, Ar), 7.44 (s, 2H, NH2), 7.51 (d, J = 8.0 Hz, 2H, Ar), 7.72 (s, 1H, Ar), 7.88 (d, J = 8.0 Hz, 2H, Ar), 8.23, 8.41 (s, 1H, NH), 11.06, 11.19 (s, 1H, CH). IR (Nujol) 3285, 3246, 1663, 1559 cm−1. Elemental analysis: calculated for C22H26N4O6S (474.53) %C 55.68, %H 5.52, %N 11.81, found %C 55.62, %H 5.53, %N 11.85. m/z 475.

(E)-4-(4-(2-(2,5-dimethoxybenzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (12)

Yield 97%, M.p. 210–211°C. 1H NMR (DMSO-d6) 1.57 (br s, 2H, CH), 1.72 (br s, 1H, CH), 1.87 (br s, 1H, CH), 2.87 (br s, 1H, CH), 3.19 (br s, 1H, CH), 3.44 (br s, 1H, CH), 3.51 (br s, 1H, CH), 3.72 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 4.47 (br s, 1H, CH), 6.96 (d, J = 8.5 Hz, 1H, Ar), 7.03 (d, J = 8.0 Hz, 1H, Ar), 7.27 (m, 1H, Ar), 7.41 (s, 2H, NH2), 7.56 (d, J = 8.5 Hz, 2H, Ar), 7.86 (d, J = 8.5 Hz, 2H, Ar), 8.27, 8.49 (s, 1H, NH), 11.21, 11.38 (s, 1H, CH). IR (Nujol) 3328, 3257, 3073, 1673 cm−1. Elemental analysis: calculated for C22H26N4O6S (474.53) %C 55.68, %H 5.52, %N 11.81, found %C 55.63, %H 5.50, %N 11.77. m/z 475.

(E)-4-(4-(2-(2,4,5-trimethoxybenzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (13)

Yield 72%, M.p. >250°C. 1H NMR (DMSO-d6) δ 1.57 (br s, 2H, CH), 1.71 (br s, 1H, CH), 1.83 (br s, 1H, CH), 2.87 (br s, 1H, CH), 3.18 (br s, 1H, CH), 3.40 (br s, 1H, CH), 3.52 (br s, 1H, CH), 3.72 (s, 3H, OCH3), 3.81 (s, 6H, OCH3), 4.47 (br s, 1H, CH), 6.70 (s, 1H, Ar), 7.26 (s, 1H, Ar), 7.42 (s, 2H, NH2), 7.57 (d, J = 8.0 Hz, 2H, Ar), 7.87 (d, J = 8.0 Hz, 2H, Ar), 8.22, 8.44 (s, 1H, NH), 11.06, 11.22 (s, 1H, CH). IR (Nujol) 3322, 3223, 1695 cm−1. Elemental analysis: calculated for C23H28N4O7S (504.56) %C 54.75, %H 5.59, %N 11.10, found %C 54.69, %H 5.60, %N 11.14. m/z 505.

(E)-4-(4-(2-(3,4,5-trimethoxybenzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (14)

Yield 76%, M.p. >250°C. 1H NMR (DMSO-d6) δ 1.59 (br s, 2H, CH), 1.73 (br s, 1H, CH), 1.86 (br s, 1H, CH), 2.52 (br s, 1H, CH), 3.10 (br s, 1H, CH), 3.41 (br s, 1H, CH), 3.52 (br s, 1H, CH), 3.67 (s, 3H, OCH3), 3.68 (s, 6H, OCH3), 4.49 (br s, 1H, CH), 6.96 (s, 2H, Ar), 7.42 (s, 2H, NH2), 7.57 (d, J = 8.0 Hz, 2H, Ar), 7.87 (d, J = 8.5 Hz, 2H, Ar), 7.89, 8.10 (s, 1H, NH), 11.27, 11.35 (s, 1H, CH). IR (Nujol) 3354, 3252, 1680, 1550 cm−1. Elemental analysis: calculated for C23H28N4O7S (504.56) %C 54.75, %H 5.59, %N 11.10, found %C 54.81, %H 5.58, %N 11.08. m/z 505.

(E)-4-(4-(2-(2-bromo-3,4-dimethoxybenzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (15)

Yield 94%, M.p.> 250°C. 1H NMR (DMSO-d6) 1.58 (br s, 2H, CH), 1.72 (br s, 1H, CH), 1.88 (br s, 1H, CH), 2.89 (br s, 1H, CH), 3.21 (br s, 1H, CH), 3.42 (br s, 1H, CH), 3.52 (br s, 1H, CH), 3.75 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 4.47 (br s, 1H, CH), 7.33 (d, J = 6.5 Hz, 1H, Ar), 7.42 (s, 2H, NH2), 7.44 (m, 1H, Ar), 7.57 (d, J = 8.0 Hz, 2H, Ar), 7.87 (d, J = 6.5 Hz, 2H, Ar), 7.89, 8.09 (s, 1H, NH), 11.32, 11.46 (s, 1H, CH). IR (Nujol) 3358, 3246, 3060, 1680, 1548 cm−1. Elemental analysis: calculated for C22H25BrN4O6S (553.43) %C 47.75, %H 4.55, %N 10.12, found %C 47.79, %H 4.54, %N 10.15. m/z 555.

(E)-4-(4-(2-((naphthalen-2-yl)methylene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (16)

Yield 71%, M.p. 220-222°C. 1H NMR (DMSO-d6) δ 1.64 (br s, 2H, CH), 1.79 (br s, 1H, CH), 1.96 (br s, 1H, CH), 2.92 (br s, 1H, CH), 3.24 (br s, 1H, CH), 3.43 (br s, 1H, CH), 3.56 (br s, 1H, CH), 4.52 (br s, 1H, CH), 7.44 (s, 2H, NH2), 7.58 (m, 6H, Ar), 7.86 (m, 3H, Ar), 7.98 (d, J = 8.2 Hz, 2H, Ar), 8.81, 8.99 (s, 1H, NH), 11.30, 11.48 (s, 1H, CH). IR (Nujol) 3253, 3069, 1680, 1619 cm−1. Elemental analysis: calculated for C24H24N4O5S (464.54) %C 62.05, %H 5.21, %N 12.06, found %C 60.76, %H 5.31, %N 11.29. m/z 464.

(E)-4-(4-(2-((1-methoxynaphthalen-2-yl)methylene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (17)

Yield 67%, M.p. >250°C. 1H NMR (DMSO-d6) δ 1.64 (br s, 2H, CH), 1.79 (br s, 1H, CH), 1.90 (br s, 1H, CH), 2.96 (br s, 1H, CH), 3.20 (br s, 1H, CH), 3.41 (br s, 1H, CH), 3.56 (br s, 1H, CH), 3.96 (s, 3H, OCH3), 4.52 (br s, 1H, CH), 7.42 (s, 2H, NH2), 7.48 (d, J = 9.0 Hz, 2H, Ar), 7.54 (m, 3H, Ar), 7.58 (d, J = 8.5 Hz, 2H, Ar), 7.90 (m, 2H, Ar), 8.01 (m, 1H, Ar), 8.72, 8.87 (s, 1H, NH), 11.26, 11.45 (s, 1H, CH). IR (Nujol) 3351, 3329, 1658 cm−1. Elemental analysis: calculated for C25H26N4O5S (494.56) %C 60.71, %H 5.30, %N 11.33, found %C 60.76, %H 5.31, %N 11.29. m/z 495.

(E)-4-(4-(2-(4-(trifluoromethyl)benzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (18)

Yield 96%, M.p. >250°C. 1H NMR (DMSO-d6) 1.60 (br s, 2H, CH), 1.73 (br s, 1H, CH),1.88 (br s, 1H, CH), 2.92 (br s, 1H, CH), 3.22 (br s, 1H, CH), 3.48 (br s, 1H, CH), 3.52 (br s, 1H, CH), 4.48 (br s, 1H, CH), 7.43 (s, 2H, NH2), 7.57 (d, J = 8.0 Hz, 2H, Ar), 7.76 (d, J = 7.5 Hz, 2H, Ar), 7.87 (m, 2H, Ar), 7.88 (m, 2H, Ar), 8.06, 8.21 (s, 1H, NH), 11.43, 11.58 (s, 1H, CH). IR (Nujol) 3364, 3240, 1680, 1556 cm−1. Elemental analysis: calculated for C21H21F3N4O4S (482.48) %C 52.28, %H 4.39, %N 11.61, found %C 52.33, %H 4.40, %N 11.58. m/z 483.

(E)-4-(4-(2-(3-fluorobenzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (19)

Yield 79%, M.p. 214-215 °C. 1H NMR (DMSO-d6) 1.58 (br s, 2H, CH), 1.72 (br s, 1H, CH), 1.89 (br s, 1H, CH), 2.88 (br s, 1H, CH), 3.23 (br s, 1H, CH), 3.44 (br s, 1H, CH), 3.51 (br s, 1H, CH), 4.47 (br s, 1H, CH), 7.22 (s, 1H, Ar), 7.43 (s, 2H, NH2), 7.48 (m, 3H, Ar), 7.57 (d, J = 8.0 Hz, 2H, Ar), 7.87 (d, J = 7.0 Hz, 2H, Ar), 7.99, 8.18 (s, 1H, NH), 11.33, 11.49 (s, 1H, CH). IR (Nujol) 3284, 3209, 1680, 1565 cm−1. Elemental analysis: calculated for C20H21FN4O4S (432.47) %C 55.54, %H 4.89, %N 12.96, found %C 55.49, %H 4.90, %N 12.99. m/z 433.

(E)-4-(4-(2-(4-fluorobenzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (20)

Yield 84%, M.p.> 250°C. 1H NMR (DMSO-d6) 1.58 (br s, 2H, CH), 1.71 (br s, 1H, CH), 1.86 (br s, 1H, CH), 2.88 (br s, 1H, CH), 3.21 (br s, 1H, CH), 3.43 (br s, 1H, CH), 3.52 (br s, 1H, CH), 4.48 (br s, 1H, CH), 7.25 (d, J = 8.5 Hz, 2H, Ar), 7.43 (s, 2H, NH2), 7.57 (d, J = 8.5 Hz, 2H, Ar), 7.71 (d, J = 7.0 Hz, 2H, Ar), 7.86 (d, J = 8.0 Hz, 2H, Ar); 7.98, 8.18 (s, 1H, NH); 11.23, 11.38 (s, 1H, CH). IR (Nujol) 3350, 3252, 1667, 1624 cm−1. Elemental analysis: calculated for C20H21FN4O4S (432.47) %C 55.54, %H 4.89, %N 12.96, found %C 55.49, %H 4.87, %N 13.00. m/z 433.

(E)-4-(4-(2-(3-nitrobenzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (21)

Yield 87%, M.p. >250°C. 1H NMR (DMSO-d6) 1.59 (br s, 2H, CH), 1.73 (br s, 1H, CH), 1.89 (br s, 1H, CH), 2.87 (br s, 1H, CH), 3.25 (br s, 1H, CH), 3.44 (br s, 1H, CH), 3.47 (br s, 1H, CH), 4.48 (br s, 1H, CH), 7.42 (s, 2H, NH2), 7.57 (d, J = 8.0 Hz, 2H, Ar), 7.71 (s, 1H, Ar), 7.87 (d, J = 8.0 Hz, 2H, Ar), 8.01 (d, J = 7.5 Hz, 2H, Ar), 8.30 (m, 1H, Ar), 8.43, 8.49 (s, 1H, NH), 11.47, 11.64 (s, 1H, CH). IR (Nujol) 3328, 3213, 3069, 1680, 1564 cm−1. Elemental analysis: calculated for C20H21N5O6S (459.48) %C 52.28, %H 4.61, %N 15.24, found %C 52.33, %H 4.59, %N 15.20. m/z 453.

(E)-4-(4-(2-(4-nitrobenzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (22)

Yield 87%, M.p.> 250°C. 1H NMR (DMSO-d6) 1.60 (br s, 2H, CH), 1.73 (br s, 1H, CH), 1.89 (br s, 1H, CH), 2.89 (br s, 1H, CH), 3.22 (br s, 1H, CH), 3.47 (br s, 1H, CH), 3.53 (br s, 1H, CH), 4.48 (br s, 1H, CH), 7.43 (s, 2H, NH2), 7.57 (d, J = 8.5 Hz, 2H, Ar), 7.87 (d, J = 8.0 Hz, 2H, Ar), 7.92 (m, 2H, Ar), 8.26 (d, J = 8.5 Hz, 2H, Ar), 8.08, 8.28 (s, 1H, NH), 11.54, 11.69 (s, 1H, CH). IR (Nujol) 3287, 3085, 1668, 1588 cm−1. Elemental analysis: calculated for C20H21N5O6S (459.48) %C 52.28, %H 4.61, %N 15.24, found %C 52.35, %H 4.60, %N 15.21. m/z 460.

(E)-4-(4-(2-(2-chlorobenzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (23)

Yield 81%, M.p. >250°C. 1H NMR (DMSO-d6) 1.59 (br s, 2H, CH), 1.73 (br s, 1H, CH), 1.88 (br s, 1H, CH), 2.99 (br s, 1H, CH), 3.20 (br s, 1H, CH), 3.44 (br s, 1H, CH), 3.50 (br s, 1H, CH), 4.48 (br s, 1H, CH), 7.39 (m, 2H, Ar), 7.42 (s, 2H, NH2), 7.49 (t, J = 7.5 Hz, 1H, Ar), 7.57 (d, J = 8.5 Hz, 2H, Ar), 7.87 (d, J = 7.5 Hz, 2H, Ar), 7.87 (m, 1H, Ar), 8.37, 8.58 (s, 1H, NH), 11.43, 11.62 (s, 1H, CH). IR (Nujol) 3240, 3074, 1677, 1538 cm−1. Elemental analysis: calculated for C20H21ClN4O4S (448.92) %C 53.51, %H 4.72, %N 12.48, found %C 53.57, %H 4.71, %N 12.44. m/z 449.

(E)-4-(4-(2-(3-chlorobenzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (24)

Yield 94%, M.p.> 250°C. 1H NMR (DMSO-d6) 1.58 (br s, 2H, CH), 1.72 (br s, 1H, CH), 1.87 (br s, 1H, CH), 2.91 (br s, 1H, CH), 3.22 (br s, 1H, CH), 3.44 (br s, 1H, CH), 3.52 (br s, 1H, CH), 4.47 (br s, 1H, CH), 7.42 (s, 2H, NH2), 7.44 (m, 2H, Ar), 7.57 (d, J = 8.0 Hz, 2H, Ar), 7.61 (m, 1H, Ar), 7.70 (m, 1H, Ar), 7.87 (d, J = 8.0 Hz, 2H, Ar), 7.97, 8.16 (s, 1H, NH), 11.34, 11.51 (s, 1H, CH). IR (Nujol) 3298, 3218, 3070, 1680, 1562 cm−1. Elemental analysis: calculated for C20H21ClN4O4S (448.92) %C 53.51, %H 4.72, %N 12.48, found %C 53.56, %H 4.73, %N 12.44. m/z 449.

(E)-4-(4-(2-(2,4-dichlorobenzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (25)

Yield 98%, M.p. 234-235°C. 1H NMR (DMSO-d6) 1.58 (br s, 2H, CH), 1.72 (br s, 1H, CH), 1.87 (br s, 1H, CH), 2.89 (br s, 1H, CH), 3.19 (br s, 1H, CH), 3.43 (br s, 1H, CH), 3.52 (br s, 1H, CH), 4.47 (br s, 1H, CH), 7.42 (s, 2H, NH2), 7.47 (m, 1H, Ar), 7.57 (d, J = 7.0 Hz, 2H, Ar), 7.68 (m, 1H, Ar), 7.87 (d, J = 6.5 Hz, 2H, Ar), 7.92 (m, 1H, Ar), 8.32, 8.53 (s, 1H, NH), 11.47, 11.66 (s, 1H, CH). IR (Nujol) 3253, 3068, 1680, 1552 cm−1. Elemental analysis: calculated for C20H20Cl2N4O4S (483.37) %C 49.70, %H 4.17, %N 11.59, found %C 49.76, %H 4.19, %N 11.54. m/z 483.

(E)-4-(4-(2-(2,5-dichlorobenzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (26)

Yield 92%, M.p.> 250°C. 1H NMR (DMSO-d6) 1.59 (br s, 2H, CH), 1.72 (br s, 1H, CH), 1.82 (br s, 1H, CH), 2.89 (br s, 1H, CH), 3.23 (br s, 1H, CH), 3.47 (br s, 1H, CH), 3.52 (br s, 1H, CH), 4.47 (br s, 1H, CH), 7.42 (s, 2H, NH2), 7.47 (m, 1H, Ar), 7.53 (m, 2H, Ar), 7.57 (d, J = 7.5 Hz, 2H, Ar), 7.87 (d, J = 7.0 Hz, 2H, Ar), 8.32, 8.52 (s, 1H, NH), 11.51, 11.73 (s, 1H, CH). IR (Nujol) 3304, 3247, 1679, 1573 cm−1. Elemental analysis: calculated for C20H20Cl2N4O4S (483.37) %C 49.70, %H 4.17, %N 11.59, found %C 49.76, %H 4.16, %N 11.55. m/z 483.

(E)-4-(4-(2-(2,6-dichlorobenzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (27)

Yield 82%, M.p.> 250°C. 1H NMR (DMSO-d6) 1.57 (br s, 2H, CH), 1.73 (br s, 1H, CH), 1.88 (br s, 1H, CH), 2.87 (br s, 1H, CH), 3.11 (br s, 1H, CH), 3.35 (br s, 1H, CH), 3.52 (br s, 1H, CH), 4.48 (br s, 1H, CH), 7.43 (s, 2H, NH2), 7.53 (m, 1H, Ar), 7.59 (d, J = 7.0 Hz, 2H, Ar), 7.71 (m, 1H, Ar), 7.86 (d, J = 6.5 Hz, 2H, Ar), 7.88 (m, 1H, Ar), 8.25, 8.39 (s, 1H, NH), 11.51, 11.67 (s, 1H, CH). IR (Nujol) 3315, 3068, 1668, 1556 cm−1. Elemental analysis: calculated for C20H20Cl2N4O4S (483.37) %C 49.70, %H 4.17, %N 11.59, found %C 49.64, %H 4.19, %N 11.63. m/z 483.

(E)-4-(4-(2-(4-(dimethylamino)benzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (28)

Yield 92%, M.p.> 250°C. 1H NMR (DMSO-d6) 1.58 (br s, 2H, CH), 1.70 (br s, 1H, CH), 1.86 (br s, 1H, CH), 2.86 (br s, 1H, CH), 2.94 (s, 6H, CH3), 3.19 (br s, 1H, CH), 3.39 (br s, 1H, CH), 3.52 (br s, 1H, CH), 4.48 (br s, 1H, CH), 6.71 (d, J = 8.5 Hz, 2H, Ar), 7.42 (s, 2H, NH2), 7.44 (d, J = 8.0, 2H, Ar), 7.57 (d, J = 8.5 Hz, 2H, Ar), 7.85 (d, J = 8.0 Hz, 2H, Ar), 7.88, 8.02 (s, 1H, NH), 10.93, 11.05 (s, 1H, CH). IR (Nujol) 3341, 3242, 1635 cm−1. Elemental analysis: calculated for C22H27N5O4S (457.55) %C 57.55, %H 5.95, %N 15.31, found %C 57.59, %H 5.96, %N 15.34. m/z 458.

(E)-4-(4-(2-(4-(diethylamino)benzylidene)hydrazinecarbonyl)piperidine-1-carbonyl)benzenesulfonamide (29)

Yield 91%, M.p.> 250°C. 1H NMR (DMSO-d6) 1.08 (t, J = 6.5 Hz, 6H, CH3), 1.58 (br s, 2H, CH), 1.70 (br s, 1H, CH), 1.85 (br s, 1H, CH), 2.86 (br s, 1H, CH), 3.19 (br s, 1H, CH), 3.39 (br s, 1H, CH), 3.47 (q, J = 6.5 Hz, 4H, CH2), 3.52 (br s, 1H, CH), 4.48 (br s, 1H, CH), 6.67 (d, J = 8.5 Hz, 2H, Ar), 7.42 (m, 4H, NH2 and Ar), 7.57 (d, J = 8.0 Hz, 2H, Ar), 7.87 (d, J = 8.0 Hz, 2H, Ar), 7.82, 7.99 (s, 1H, NH), 10.89, 11.03 (s, 1H, CH). IR (Nujol) 3327, 3218, 1659, 1614 cm−1. Elemental analysis: calculated for C24H31N5O4S (485.60) %C 59.36, %H 6.43, %N 14.42, found %C 59.42, %H 6.44, %N 14.37. m/z 486.

3.2. Carbonic Anhydrase Inhibition

An Applied Photophysics stopped-flow instrument was used for assaying the CA-catalyzed CO2 hydration activity [44]. Phenol red (at a concentration of 0.2 mM) was used as an indicator, working at the absorbance maximum of 557 nm, with 20 mM HEPES (pH 7.5) as the buffer, and 20 mM Na2SO4 (for maintaining a constant ionic strength), following the initial rates of the CA-catalyzed CO2 hydration reaction for a period of 10–100 s. The CO2 concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. For each inhibitor at least six traces of the initial 5–10% of the reaction were used for determining the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of inhibitor (0.1 mM) were prepared in 10% DMSO aqueous solution and dilutions up to 0.01 nM were done thereafter with the assay buffer. Inhibitor and enzyme solutions were preincubated together for 15 min at room temperature prior to the assay, in order to allow for the formation of the E-I complex. The inhibition constants were obtained by non-linear least squares methods using PRISM 3 and the Cheng–Prusoff equation, as reported earlier [45,46,47] and represent the mean from at least three different determinations. All CA isoforms were recombinant ones obtained in-house as reported earlier. Their concentrations in the assay system were 5.7–11.9 nM [41,48,49].

3.3. Molecular Docking

Molecular docking simulations were carried out by using the crystal structures of CAII (PDB ID 3HS4) [50], CAIX (PDB ID 3IAI) [51] and CAXII (PDB ID 1JD0) [52] in complex with the inhibitor AAZ that was used as a reference compound in this study. The protein structures were prepared as described elsewhere [53]. Ligand structures were submitted to a preliminary conjugate gradient minimization by using AMMP tool implemented in VEGA ZZ software [54]. The minimized structures underwent a conformational search by following a Monte Carlo procedure as implemented in VEGA ZZ. The lowest energy conformation was selected and further optimized by the PM7 semi-empirical method using MOPAC 2016 [55]. The prepared ligands were docked to the CAII, CAIX and CAXII binding pockets by means of GOLD V 5.8.1 [56]. The binding site was defined in order to include all the residues within 10 Å from the co-crystallized ligand. In considering the conserved binding motif of the sulfonamide portion, a scaffold constraint was applied to restrict the docking solutions to those in which this moiety assumes a binding orientation similar to that observed for the native ligand AAZ in the experimental structures. The option “never dock a ligand when a constraint is physically impossible” was checked. All the ligands were submitted to ten genetic algorithms runs following the docking protocols reported elsewhere [57,58] The best docking pose was chosen for the analysis and representation.

4. Conclusions

In the present study, we described a small library of benzenesulfonamides as potential hCA Is, endowed with a benzenesulfonamide-type zinc-binding group (ZBG) connected by a carbonyl bridge to a piperidine ring, which provide an appropriate orientation and connections of the two tails with both the hydrophilic and hydrophobic halves of the active site. The 4-methoxyphenylhydrazone 9 showed the best selectivity against hCA II that might be due the tail orientation producing hydrophobic interactions with the enzyme’s active site. The dimethoxyphenylhydrazone 10 and 11 as well as the 3-halophenylhydrazones 19 and 24 showed the best selectivity against the tumor-associated hCA IX and hCA XII isoforms. The tails of these compounds established hydrophobic interactions with the active site of hCA IX and hCA XII; conversely, no interaction of the tails was possible in the hCA II binding site. Overall, these results indicate that through small structural changes of the benzylidene tail portion of these hCAI inhibitors, it is possible to modulate both their inhibitory activity and hCA isoform selectivity.

Supplementary Materials

The following supporting information can be downloaded at: https://0-www-mdpi-com.brum.beds.ac.uk/article/10.3390/molecules28010091/s1, 1H-NMR spectra of hydrazones 8, 9, 10, 11, 19 and 24.

Author Contributions

Conceptualization, V.O., G.B. and C.T.S.; software, S.V.; validation, V.O., G.B. and C.T.S.; formal analysis, S.V.; investigation, D.M. and A.A.; resources, C.T.S. and V.O.; data curation, D.M. and A.A.; writing—original draft preparation, D.M. and A.A.; writing—review and editing, D.M., S.V., A.A., G.B., C.T.S. and V.O.; visualization, D.M., A.A. and S.V.; supervision, V.O. and C.T.S.; funding acquisition, V.O. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Italian Ministero dell’Istruzione, Università e della Ricerca, Italy; grant PRIN 2017, Prot. No. 2010E84AA4_002.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds 5–29 are available from the authors.

References

  1. Alterio, V.; Di Fiore, A.; D’Ambrosio, K.; Supuram, C.T.; De Simone, G. Multiple binding modes of inhibitors to carbonic anhydrases: How to design specific drugs targeting 15 different isoforms? Chem. Rev. 2012, 112, 4421–4468. [Google Scholar] [CrossRef] [Green Version]
  2. Supuran, C.T. Structure and function of carbonic anhydrases. Biochem. J. 2016, 473, 2023–2032. [Google Scholar] [CrossRef]
  3. Mishra, C.B.; Tiwari, M.; Supuran, C.T. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: Where are we today? Med. Res. Rev. 2020, 40, 2485–2565. [Google Scholar] [CrossRef] [PubMed]
  4. Supuran, C.T. Novel carbonic anhydrase inhibitors. Future Med. Chem. 2021, 13, 1935–1937. [Google Scholar] [CrossRef]
  5. Carta, F.; Supuran, C.T.; Scozzafava, A. Novel therapies for glaucoma: A patent review 2007–2011. Expert Opin. Ther. Pat. 2012, 22, 79–88. [Google Scholar] [CrossRef] [PubMed]
  6. Aggarwal, M.; Boone, C.D.; Kondeti, B. Structural annotation of human carbonic anhydrases. J. Enz. Inhib. Med. Chem. 2013, 28, 267–277. [Google Scholar] [CrossRef] [PubMed]
  7. Carta, F.; Scozzafava, A.; Supuran, C.T. Sulfonamides: A patent review (2008–2012). Expert Opin. Ther. Pat. 2012, 22, 747–758. [Google Scholar] [CrossRef] [PubMed]
  8. Pollard, A.; Shephard, F.; Freed, J.; Liddell, S.; Chakrabarti, L. Mitochondrial proteomic profiling reveals increased carbonic anhydrase II in aging and neurodegeneration. Aging-Us. 2016, 8, 2425–2436. [Google Scholar] [CrossRef] [Green Version]
  9. Jarvinen, P.; Kivela, A.J.; Nummela, P.; Lepisto, A.; Ristimaki, A.; Parkkila, S. Carbonic anhydrase II: A novel biomarker for pseudomyxoma peritonei. APMIS 2017, 125, 207–212. [Google Scholar] [CrossRef]
  10. Pastorekova, S.; Parkkila, S.; Parkkila, A.K.; Opavsky, R.; Zelnik, V.; Saarnio, J.; Pastorek, J. Carbonic anhydrase IX, MN/CA IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997, 112, 398–408. [Google Scholar] [CrossRef]
  11. Ivanov, S.; Liao, S.Y.; Ivanova, A.; Danilkovitch-Miagkova, A.; Tarasova, N.; Weirich, G.; Merrill, M.J.; Proescholdt, M.A.; Oldfield, E.H.; Lee, J.; et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol. 2001, 158, 905–919. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Ondriskova, E.; Debreova, M.; Pastorekova, S. Tumor-associated carbonic anhydrases IX and XII. In Carbonic Anhydrases as Biocatalysts: From Theory to Medical and Industrial Applications; Supuran, C.T., Simone, G., Eds.; Elsevier: Amsterdam, the Netherlands, 2015; pp. 169–206. [Google Scholar]
  13. Türeci, O.; Sahin, U.; Vollmar, E.; Siemer, S.; Göttert, E.; Seitz, G.; Parkkila, A.K.; Shah, G.N.; Grubb, J.H.; Pfreundschuh, M.; et al. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc. Natl. Acad. Sci. USA 1998, 95, 7608–7613. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Ivanov, S.V.; Kuzmin, I.; Wei, M.H.; Pack, S.; Geil, L.; Johnson, B.E.; Stanbridge, E.J.; Lerman, M.I. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc. Natl. Acad. Sci. USA 1998, 95, 12596–12601. [Google Scholar] [CrossRef] [Green Version]
  15. Karhumaa, P.; Kaunisto, K.; Parkkila, S.; Waheed, A.; Pastorekova, S.; Pastorek, J.; Sly, W.S.; Rajaniemi, H. Expression of the transmembrane carbonic anhydrases, CA IX and CA XII, in the human male excurrent ducts. Mol. Hum. Reprod. 2000, 7, 611–616. [Google Scholar] [CrossRef]
  16. Parkkila, S.; Parkkila, A.K.; Saarnio, J.; Kivela, J.; Karttunen, T.; Kaunisto, K.; Waheed, A.; Sly, W.S.; Tureci, O.; Virtanen, I.; et al. Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors. Histochem. Cytochem. 2000, 48, 1601–1608. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Singh, S.; Lomelino, C.L.; Mboge, M.Y.; Frost, S.C.; McKenna, R. Cancer drug development of carbonic anhydrase inhibitors beyond the active site. Molecules 2018, 23, 1045. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Pastorek, J.; Pastorekova, S. Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: From biology to clinical use. Semin. Cancer. Biol. 2015, 31, 52–64. [Google Scholar] [CrossRef]
  19. Gieling, R.G.; Williams, K.J. Carbonic anhydrase IX as a target for metastatic disease. Bioorg. Med. Chem. 2013, 21, 1470–1476. [Google Scholar] [CrossRef]
  20. Gemma, S.; Kukreja, G.; Fattorusso, C.; Persico, M.; Romano, M.P.; Altarelli, M.; Savini, L.; Campiani, G.; Fattorusso, E.; Basilico, N. Synthesis of N1-arylidene-N2-quinolyl-and N2-acrydinylhydrazones as potent antimalarial agents active against CQ-resistant P. falciparum strains. Bioorg. Med. Chem. Lett. 2006, 16, 5384–5388. [Google Scholar] [CrossRef]
  21. Inam, A.; Siddiqui, S.M.; Macedo, T.S.; Moreira, D.R.M.; Leite, A.C.L.; Soares, M.B.P.; Azam, A. Design, synthesis and biological evaluation of 3-[4-(7-chloro-quinolin-4-yl)-piperazin-1-yl]-propionic acid hydrazones as antiprotozoal agents. Eur. J. Med. Chem. 2014, 75, 67–76. [Google Scholar] [CrossRef]
  22. Terzioglu, N.; Gürsoy, A. Synthesis and anticancer evaluation of some new hydrazone derivatives of 2, 6-dimethylimidazo [2,1-b][1,3,4] thiadiazole-5-carbohydrazide. Eur. J. Med. Chem. 2003, 38, 781–786. [Google Scholar] [CrossRef] [PubMed]
  23. Cocco, M.T.; Congiu, C.; Lilliu, V.; Onnis, V. Synthesis and in vitro antitumoral activity of new hydrazinopyrimidine-5-carbonitrile derivatives. Bioorg. Med. Chem. 2006, 14, 366–372. [Google Scholar] [CrossRef] [PubMed]
  24. Nasr, T.; Bondock, S.; Youns, M. Anticancer activity of new coumarin substituted hydrazide–hydrazone derivatives. Eur. J. Med. Chem. 2014, 76, 539–548. [Google Scholar] [CrossRef] [PubMed]
  25. Easmon, J.; Pürstinger, G.; Thies, K.-S.; Heinisch, G.; Hofmann, J. Synthesis, structure- activity relationships, and antitumor studies of 2-benzoxazolyl hydrazones derived from alpha-(N)-acyl heteroaromatics. J. Med. Chem. 2006, 49, 6343–6350. [Google Scholar] [CrossRef]
  26. Baldisserotto, A.; Demurtas, M.; Lampronti, I.; Tacchini, M.; Moi, D.; Balboni, G.; Vertuani, S.; Manfredini, S.; Onnis, V. In-vitro evaluation of antioxidant, antiproliferative and photo-protective activities of benzimidazolehydrazone derivatives. Pharmauceticals 2020, 13, 68. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Koc, H.C.; Atlihan, I.; Mega-Tiber, P.; Orun, O.; Kucukguzel, S.G. Synthesis of some novel hydrazide-hydrazones derived from etodolac as potential anti-prostate cancer agents. J. Res.Pharm. 2022, 26, 1018–1029. [Google Scholar] [CrossRef]
  28. Güzel-Akdemir, Ö.; Angeli, A.; Supuran, C.T.; Akdemir, A. Novel Indole-Based Hydrazones as Potent Inhibitors of the α-class Carbonic Anhydrase from Pathogenic Bacterium Vibrio cholerae. Int. J. Mol. Sci. 2020, 21, 3131. [Google Scholar] [CrossRef]
  29. Demir-Yazıcı, K.; Bua, S.; Nurgül Mutlu Akgüneş, N.M.; Akdemir, A.; Supuran, C.T.; Güzel-Akdemir, O. Indole-Based Hydrazones Containing A Sulfonamide Moiety as Selective Inhibitors of Tumor-Associated Human Carbonic Anhydrase Isoforms IX and XII. Int. J. Mol. Sci. 2019, 20, 2354. [Google Scholar] [CrossRef] [Green Version]
  30. Brichet, J.; Rodrigo Arancibia, R.; Berrino, E.; Supuran, C.T. Bioorganometallic derivatives of 4-hydrazino-benzenesulphonamide as carbonic anhydrase inhibitors: Synthesis, characterisation and biological evaluation. J. Enz. Inhib. Med. Chem. 2020, 35, 622–628. [Google Scholar] [CrossRef] [Green Version]
  31. Kucukoglu, K.; Gul, H.I.; ParhamTaslimi, P.; Gulcin, I.; Supuran, C.T. Investigation of inhibitory properties of some hydrazone compounds on hCA I, hCA II and AChE enzymes. Bioorg. Chem. 2019, 86, 316–321. [Google Scholar] [CrossRef]
  32. Sharma, V.; Kumar, R.; Bua, S.; Supuran, C.T.; Sharma, P.K. Synthesis of novel benzenesulfonamide bearing 1,2,3-triazole linked hydroxy-trifluoromethylpyrazolines and hydrazones as selective carbonic anhydrase isoforms IX and XII inhibitors. Bioorg. Chem. 2019, 85, 198–208. [Google Scholar] [CrossRef] [PubMed]
  33. Abdel-Aziz, A.A.-M.; El-Azab, A.S.; El-Enin, M.A.A.; Almehizia, A.A.; Supuran, C.T.; Nocentini, A. Synthesis of novel isoindoline-1,3-dione-based oximes and benzenesulfonamide hydrazones as selective inhibitors of the tumor-associated carbonic anhydrase IX. Bioorg. Chem. 2018, 80, 706–713. [Google Scholar] [CrossRef] [PubMed]
  34. Celebioglu, H.U.; Erden, Y.; Hamurcu, F.; Taslimi, P.; Şentürk, O.S.; Özmen, Ü.Ö.; Tuzun, B.; Gulçin, İ. Cytotoxic effects, carbonic anhydrase isoenzymes, α-glycosidase and acetylcholinesterase inhibitory properties, and molecular docking studies of heteroatom-containing sulfonyl hydrazone derivatives. J. Biomol. Struct. Dyn. 2021, 3, 5539–5550. [Google Scholar] [CrossRef] [PubMed]
  35. Yamali, C.; Sakagami, H.; Uesawa, Y.; Kurosaki, K.; Satoh, K.; Masuda, Y.; Yokose, S.; Ece, A.; Bua, S.; Angeli, A.; et al. Comprehensive study on potent and selective carbonic anhydrase inhibitors: Synthesis, bioactivities and molecular modelling studies of 4-(3-(2-arylidenehydrazine-1-carbonyl)-5-(thiophen-2-yl)-1H-pyrazole-1-yl) benzenesulfonamides. Eur. J. Med. Chem. 2021, 217, 113351. [Google Scholar] [CrossRef] [PubMed]
  36. Queen, A.; Khan, P.; Idrees, D.; Azama, A.; Hassan, I. Biological evaluation of p-toluene sulphonylhydrazone as carbonic anhydrase IX inhibitors: An approach to fight hypoxia-induced tumors. Int. J. Biol. Mac. 2018, 106, 840–850. [Google Scholar] [CrossRef] [PubMed]
  37. Moi, D.; Deplano, A.; Angeli, A.; Balboni, G.; Supuran, C.T.; Onnis, V. Synthesis of Sulfonamides Incorporating Piperidinyl-Hydrazidoureido and Piperidinyl Hydrazidothioureido Moieties and Their Carbonic Anhydrase I, II, IX and XII Inhibitory Activity. Molecules 2022, 27, 5370. [Google Scholar] [CrossRef]
  38. Nocentini, A.; Moi, D.; Deplano, A.; Osman, S.M.; AlOthman, Z.A.; Balboni, G.; Supuran, C.T.; Onnis, V. Sulfonamide/sulfamate switch with a series of piperazinylureido derivatives: Synthesis, kinetic and in silico evaluation as carbonic anhydrase isoforms I, II, IV, and IX inhibitors. Eur. J. Med. Chem. 2020, 186, 111896. [Google Scholar] [CrossRef]
  39. Moi, D.; Nocentini, A.; Deplano, A.; Balboni, G.; Supuran, C.T.; Onnis, V. Structure-activity relationship with pyrazoline-based aromatic sulfamates as carbonic anhydrase isoforms I, II, IX and XII inhibitors: Synthesis and biological evaluation. Eur. J. Med. Chem. 2019, 182, 111638. [Google Scholar] [CrossRef]
  40. Nocentini, A.; Moi, D.; Deplano, A.; Balboni, G.; Salvadori, S.; Onnis, V.; Supuran, C.T. Synthesis and biological evaluation of novel pyrazoline-based aromatic sulfamates with potent carbonic anhydrase isoforms II, IV and IX inhibitory efficacy. Bioorg. Chem. 2018, 77, 633–639. [Google Scholar] [CrossRef]
  41. Nocentini, A.; Moi, D.; Deplano, A.; Balboni, G.; Onnis, V.; Supuran, C.T. Discovery of thiazolin-4-one-based aromatic sulfamates as a new class of carbonic anhydrase isoforms I, II, IV, and IX inhibitors. Bioorg. Chem. 2018, 77, 293–299. [Google Scholar] [CrossRef]
  42. Nocentini, A.; Moi, D.; Deplano, A.; Osman, S.M.; AlOthman, Z.A.; Piras, V.; Balboni, G.; Supuran, C.T.; Onnis, V. Appliance of the piperidinyl-hydrazidoureido linker to benzenesulfonamide compounds: Synthesis, in vitro and in silico evaluation of potent carbonic anhydrase II, IX and XII inhibitors. Bioorg. Chem. 2020, 98, 103728. [Google Scholar] [CrossRef]
  43. Lima, P.C.; Lima, L.M.; da Silva, K.C.M.; Léda, P.H.O.; de Miranda, A.L.P.; Fraga, C.A.M.; Barreiro, E.J. Synthesis and analgesic activity of novel N-acylarylhydrazones and isosters, derived from natural safrole. Eur. J. Med. Chem. 2020, 35, 187–203. [Google Scholar] [CrossRef] [PubMed]
  44. Khalifah, R.G. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J. Biol. Chem. 1971, 246, 2561–2573. [Google Scholar] [CrossRef] [PubMed]
  45. Kiss, L.E.; Ferreira, H.S.; Torrão, L.; Bonifácio, M.J.; Palma, P.N.; Soares-da-Silva, P.; Learmonth, D.A. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J. Med. Chem. 2010, 53, 3396–3411. [Google Scholar] [CrossRef] [PubMed]
  46. Vullo, D.; Del Prete, S.; Nocentini, A.; Osman, S.M.; AlOthman, Z.A.; Capasso, C.; Bozdag, M.; Carta, F.; Gratteri, P.; Supuran, C.T. Dithiocarbamates effectively inhibit the β-carbonic anhydrase from the dandruff-producing fungus Malassezia Globose Bioorg. Med. Chem. 2017, 25, 1260–1265. [Google Scholar] [CrossRef]
  47. Del Prete, S.; Angeli, A.; Ghobril, C.; Hitce, J.; Clavaud, C.; Marat, X.; Supuran, C.T.; Capasso, C. Sulfonamide Inhibition Profile of the β-Carbonic Anhydrase from Malassezia restricta, An Opportunistic Pathogen Triggering Scalp Conditions. Metabolites 2020, 10, 39. [Google Scholar] [CrossRef] [Green Version]
  48. Nocentini, A.; Bonardi, A.; Gratteri, P.; Cerra, B.; Gioiello, A.; Supuran, C.T. Steroids interfere with human carbonic anhydrase activity by using alternative binding mechanisms. J. Enzyme Inhib. Med. Chem. 2018, 33, 1453–1459. [Google Scholar] [CrossRef] [Green Version]
  49. Bonardi, A.; Vermelho, A.B.; da Silva Cardoso, V.; de Souza Pereira, M.C.; da Silva Lara, L.; Selleri, S.; Gratteri, P.; Supuran, C.T.; Nocentini, A. N-Nitrosulfonamides as Carbonic Anhydrase Inhibitors: A Promising Chemotype for Targeting Chagas Disease and Leishmaniasis. ACS Med. Chem. Lett. 2018, 10, 413–418. [Google Scholar] [CrossRef]
  50. Sippel, K.H.; Robbins, A.H.; Domsic, J.; Genis, C.; Agbandje-McKenna, M.; McKenna, R. High-resolution structure of human carbonic anhydrase II complexed with acetazolamide reveals insights into inhibitor drug design. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2009, 65, 992–995. [Google Scholar] [CrossRef] [Green Version]
  51. Alterio, V.; Hilvo, M.; Di Fiore, A.; Supuran, C.T.; Pan, P.; Parkkila, S.; Scaloni, A.; Pastorek, J.; Pastorekova, S.; Pedone, C.; et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc. Natl. Acad. Sci. USA 2009, 106, 16233–16238. [Google Scholar] [CrossRef]
  52. Whittington, D.A.; Waheed, A.; Ulmasov, B.; Shah, G.N.; Grubb, J.H.; Sly, W.S.; Christianson, D.V. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells. Proc. Natl. Acad. Sci. USA 2001, 98, 9545–9550. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Baron, G.; Borella, S.; Della Vedova, L.; Vittorio, S.; Vistoli, G.; Carini, M.; Aldini, G.; Altomare, A. An integrated metabolomic and proteomic approach for the identification of covalent inhibitors of the main protease (Mpro) of SARS-CoV-2 from crude natural extracts. Talanta 2022, 252, 123824.1–123824.13. [Google Scholar] [CrossRef] [PubMed]
  54. Pedretti, A.; Mazzolari, A.; Gervasoni, S.; Fumagalli, L.; Vistoli, G. The VEGA suite of programs: An versatile platform for cheminformatics and drug design projects. Bioinformatics 2021, 37, 1174–1175. [Google Scholar] [CrossRef]
  55. Dewar, M.J.S.; Walter Thiel, W. Ground states of molecules. 38. The MNDO method. Approximations and parameters. J. Am. Chem. Soc. 1977, 99, 4899–4907. [Google Scholar] [CrossRef]
  56. Jones, G.; Willett, P.; Glen, R.C.; Leach, A.R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727–748. [Google Scholar] [CrossRef] [Green Version]
  57. De Luca, L.; Germanò, M.P.; Fais, A.; Pintus, F.; Buemi, M.R.; Vittorio, S.; Mirabile, S.; Rapisarda, A.; Gitto, R. Discovery of a new potent inhibitor of mushroom tyrosinase (Agaricus bisporus) containing 4-(4-hydroxyphenyl)piperazin-1-yl moiety. Bioorg. Med. Chem. 2020, 28, 115497. [Google Scholar] [CrossRef]
  58. Vittorio, S.; Ielo, L.; Mirabile, S.; Gitto, R.; Fais, A.; Floris, S.; Rapisarda, A.; Germanò, M.P.; De Luca, L. 4-Fluorobenzylpiperazine-Containing Derivatives as Efficient Inhibitors of Mushroom Tyrosinase. ChemMedChem 2020, 15, 1757–1764. [Google Scholar] [CrossRef]
Molecules 28 00091 sch001 550
Scheme 1. General synthetic procedure for hydrazonosulfonamides 5–29. Reagents and conditions: (i) EDCI, HOBt, dry CH3CN r.t. 12h, 77% yield; (ii) NH2NH2·H2O, absolute EtOH, reflux 3h, 78% yield; substituted arylaldehydes, absolute EtOH, reflux 6h, 52–98% yield.
Scheme 1. General synthetic procedure for hydrazonosulfonamides 5–29. Reagents and conditions: (i) EDCI, HOBt, dry CH3CN r.t. 12h, 77% yield; (ii) NH2NH2·H2O, absolute EtOH, reflux 3h, 78% yield; substituted arylaldehydes, absolute EtOH, reflux 6h, 52–98% yield.
Molecules 28 00091 sch001
Molecules 28 00091 g001 550
Figure 1. Binding modes of compounds 8 (orange sticks) and 9 (green sticks): (A) binding mode of 8 and 9 to hCA II active site; (B) binding mode of 8 and 9 to hCA IX active site; (C) binding mode of 8 and 9 to hCA XII active site. The residues of the binding site involved in the interactions with the inhibitors are shown as sticks. H-bond interactions are displayed as yellow dashed lines.
Figure 1. Binding modes of compounds 8 (orange sticks) and 9 (green sticks): (A) binding mode of 8 and 9 to hCA II active site; (B) binding mode of 8 and 9 to hCA IX active site; (C) binding mode of 8 and 9 to hCA XII active site. The residues of the binding site involved in the interactions with the inhibitors are shown as sticks. H-bond interactions are displayed as yellow dashed lines.
Molecules 28 00091 g001
Molecules 28 00091 g002 550
Figure 2. Docking poses of hydrazones 10, 11, 19 and 24 to hCA II active site: (A) hydrazone 10; (B) hydrazone 11; (C) hydrazone 19; (D) hydrazone 24. The residues of the binding site involved in the interactions with the inhibitors are shown as sticks. H-bond interactions are displayed as yellow dashed lines.
Figure 2. Docking poses of hydrazones 10, 11, 19 and 24 to hCA II active site: (A) hydrazone 10; (B) hydrazone 11; (C) hydrazone 19; (D) hydrazone 24. The residues of the binding site involved in the interactions with the inhibitors are shown as sticks. H-bond interactions are displayed as yellow dashed lines.
Molecules 28 00091 g002
Molecules 28 00091 g003 550
Figure 3. Docking poses of hydrazones 10, 11, 19, and 24 to hCA IX active site: (A) hydrazone 10; (B) hydrazone 11; (C) hydrazone 19; (D) hydrazone 24. The residues of the binding site involved in the interactions with the inhibitors are shown as sticks. H-bond and halogen bond interactions are displayed as yellow and blue dashed lines, respectively.
Figure 3. Docking poses of hydrazones 10, 11, 19, and 24 to hCA IX active site: (A) hydrazone 10; (B) hydrazone 11; (C) hydrazone 19; (D) hydrazone 24. The residues of the binding site involved in the interactions with the inhibitors are shown as sticks. H-bond and halogen bond interactions are displayed as yellow and blue dashed lines, respectively.
Molecules 28 00091 g003
Molecules 28 00091 g004 550
Figure 4. Docking poses of hydrazones 10, 11, 19 and 24 to hCA XII active site: (A) hydrazone 10; (B) hydrazone 11; (C) hydrazone 19; (D) hydrazone 24. The residues of the binding site involved in the interactions with the inhibitors are shown as sticks. H-bonds are displayed as yellow dashed lines.
Figure 4. Docking poses of hydrazones 10, 11, 19 and 24 to hCA XII active site: (A) hydrazone 10; (B) hydrazone 11; (C) hydrazone 19; (D) hydrazone 24. The residues of the binding site involved in the interactions with the inhibitors are shown as sticks. H-bonds are displayed as yellow dashed lines.
Molecules 28 00091 g004
Table
Table 1. Inhibition data of human CA isoforms I, II, IX and XII by hydrazones 5–29 and AAZ as standard inhibitor.
Table 1. Inhibition data of human CA isoforms I, II, IX and XII by hydrazones 5–29 and AAZ as standard inhibitor.
CmpdArKI (nM) 1
CAICAIICAIXCAXIICAII/CAI SelectivityCAII/CAIX SelectivityCAII/CAXII Selectivity
5Molecules 28 00091 i00118.54.4134.318.04.27.84.1
6Molecules 28 00091 i00232355.6248.113.9575.68.62.5
7Molecules 28 00091 i00345.52.9455.18.5515.518.72.9
8Molecules 28 00091 i004382.544.338.419.48.60.90.4
9Molecules 28 00091 i005389.54.4832010286.971,422.8
10Molecules 28 00091 i0061885159.615.49.2111.80.10.06
11Molecules 28 00091 i00734455.119.68.056.20.40.1
12Molecules 28 00091 i00824.31.7544.925.813.925.714.7
13Molecules 28 00091 i00941.83.7852.126.111.113.86.9
14Molecules 28 00091 i010384.567.639.732.45.70.60.5
15Molecules 28 00091 i011153565.558.936.523.40.90.6
16Molecules 28 00091 i01240002091239.3619.10.60.04
17Molecules 28 00091 i01333425.216.415.313.30.60.6
18Molecules 28 00091 i014175037.467.555.746.81.81.5
19Molecules 28 00091 i01539292.419.710.24.20.20.1
20Molecules 28 00091 i01634017.141.624.819.92.41.4
21Molecules 28 00091 i017182546.214929.439.53.3 0.6
22Molecules 28 00091 i018383.54.9264.253.177.913.08.2
23Molecules 28 00091 i019482.56.5123.414.474.13.62.2
24Molecules 28 00091 i020398.555.436.117.37.20.70.3
25Molecules 28 00091 i0213366.6548.737.250.57.35.6
26Molecules 28 00091 i0228003.6457.741.9219.815.811.5
27Molecules 28 00091 i02324.63.5754.268.76.915.219.2
28Molecules 28 00091 i02410605.3915922.9196.729.54.2
29Molecules 28 00091 i02545.04.2764.142.110.515.09.9
AAZ 250.012.025.05.720.82.10.5
1 Mean from three different assays, using a stopped-flow technique (errors were in the range of ±5–10% of the reported values).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Moi, D.; Vittorio, S.; Angeli, A.; Balboni, G.; Supuran, C.T.; Onnis, V. Investigation on Hydrazonobenzenesulfonamides as Human Carbonic Anhydrase I, II, IX and XII Inhibitors. Molecules 2023, 28, 91. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules28010091

AMA Style

Moi D, Vittorio S, Angeli A, Balboni G, Supuran CT, Onnis V. Investigation on Hydrazonobenzenesulfonamides as Human Carbonic Anhydrase I, II, IX and XII Inhibitors. Molecules. 2023; 28(1):91. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules28010091

Chicago/Turabian Style

Moi, Davide, Serena Vittorio, Andrea Angeli, Gianfranco Balboni, Claudiu T. Supuran, and Valentina Onnis. 2023. "Investigation on Hydrazonobenzenesulfonamides as Human Carbonic Anhydrase I, II, IX and XII Inhibitors" Molecules 28, no. 1: 91. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules28010091

Article Metrics

Back to TopTop